Theory Paper IIDrNB Cardiology – Theory Notes
ADVANCES IN DIAGNOSIS OF HYPERTROPHIC CARDIOMYOPATHY
IADVANCES IN ELECTROCARDIOGRAPHY AND ARTIFICIAL INTELLIGENCE
- Deep-Learning Artificial Intelligence ECG (AI-ECG): Convolutional neural networks trained on standard 12-lead ECG waveforms detect subtle, sub-visual depolarization and repolarization signatures of Hypertrophic Cardiomyopathy (HCM) with an Area Under the Curve (AUC) exceeding 0.95 (Ko et al., JACC 2020).
- Clinical Utility: Enables pre-phenotypic screening of genotype-positive, phenotype-negative family members, flag-alerting Apical HCM (which is frequently missed on routine TTE without contrast), and tracking electrophysiological reverse remodeling (rapid reductions in AI-ECG HCM probability scores and Sokolow-Lyon voltages) in patients treated with Cardiac Myosin Inhibitors (Mavacamten / Aficamten).
IIADVANCES IN MULTIMODALITY ECHOCARDIOGRAPHY (ESC 2023 / AHA-ACC 2024 GUIDELINES)
- 2D Speckle-Tracking Global Longitudinal Strain (GLS) and Mechanical Dispersion:
- Subclinical Systolic Dysfunction and Fibrosis Mapping: Even when radial hypercontractility maintains a supranormal LVEF (65 to 75 percent), regional longitudinal strain is markedly impaired (often worse than -10% to -12%) in hypertrophied septal segments, correlating directly with histological myofibrillar disarray and replacement fibrosis (CMR LGE).
- Bull’s-Eye Phenocopy Differentiation: Polar strain maps distinguish Sarcomeric Septal HCM (focal septal strain loss) and Apical HCM (apical strain loss — “reverse cherry-on-top”) from Cardiac Amyloidosis (relative apical sparing — “cherry-on-top”) and Fabry Disease (basal inferolateral strain loss).
- Mechanical Dispersion: Prolonged standard deviation of time-to-peak strain across 17 segments (>60 to 65 ms) independently predicts Ventricular Tachycardia and Sudden Cardiac Death (SCD), and progressive global GLS decline warns of impending transition to “End-Stage / Burned-Out” HCM (LVEF <50%).
- Contrast-Enhanced and 3D Echocardiography:
- Ultrasound Enhancing Agents (Echo Contrast — Class I): Mandatory whenever the apex is suboptimally visualized to unmask Apical HCM (Yamaguchi syndrome), Thin-Walled Apical Pouch / Apical Aneurysm (a major SCD and stroke risk factor missed by unenhanced 2D TTE in >40% of cases), and apical mural thrombus.
- 3D Echocardiography: Eliminates geometric assumptions in asymmetric LVH mass quantification and provides en-face surgical visualization of intrinsic mitral valve apparatus abnormalities—specifically elongated anterior/posterior mitral leaflets, anomalous direct papillary muscle insertion into the anterior mitral leaflet, and anteriorly displaced/bifid papillary muscles—that drive Systolic Anterior Motion (SAM) even with mild septal hypertrophy (<18 mm).
- Physiological Exercise Stress Echocardiography (Class I): Upright treadmill or bicycle exercise echocardiography (never dobutamine) is mandatory in symptomatic patients with resting/Valsalva gradients <50 mmHg to unmask latent dynamic LVOT obstruction (>=50 mmHg).
IIIADVANCES IN CARDIAC MAGNETIC RESONANCE (CMR — CLASS I REFERENCE STANDARD)
- Quantitative Late Gadolinium Enhancement (LGE — Major SCD Risk Modifier):
- Volumetric Threshold: CMR has shifted from binary presence/absence of mid-wall patchy LGE (typically at the RV-LV septal insertion points and segments of maximal hypertrophy) to quantitative percentage of total LV mass (using the >=6 standard deviations above normal remote myocardium method).
- Guideline Actionability (2024 AHA/ACC & 2023 ESC): Extensive LGE comprising 15 percent or more of LV mass confers a >2-fold increase in sudden death risk and is an established Class IIa major risk factor for Primary-Prevention ICD implantation (and is integrated into the 2023 ESC HCM-SCD risk refinement).
- Parametric Mapping (Native T1 Mapping and Extracellular Volume [ECV]) and Diffusion Tensor CMR:
- Diffuse Interstitial Fibrosis: Elevated Native T1 and ECV (>28 to 30%) quantify diffuse reactive interstitial collagen expansion before macroscopic replacement scar (LGE) develops.
- Differentiating Phenocopies on Native T1: Low Native T1 is highly characteristic of Anderson-Fabry Disease (intracellular glycosphingolipid storage, prior to pseudonormalization from basal inferolateral fibrosis) or iron overload, whereas markedly elevated Native T1 (>1,100–1,150 ms) and ECV (>40%) with nulling difficulty are diagnostic of Cardiac Amyloidosis.
- In-Vivo Diffusion Tensor CMR (DT-CMR) and Quantitative Stress Perfusion: DT-CMR non-invasively maps myofibrillar disarray (reduced fractional anisotropy) in vivo, while quantitative adenosine-stress perfusion CMR detects severe coronary microvascular dysfunction (subendocardial hypoperfusion driving ischemia and scar).
| Diagnostic Modality | Advanced Parameter / Biomarker | Actionable Diagnostic or Prognostic Cut-off (2023 ESC / 2024 AHA-ACC) |
|---|---|---|
| Quantitative LGE-CMR | Replacement myocardial fibrosis (% of LV mass) | LGE >= 15% of LV mass = Major independent Class IIa indication for Primary-Prevention ICD |
| CMR / Contrast Echo | LV Apical Aneurysm (with transmural apical LGE) | Independent Class IIa indication for ICD + Oral Anticoagulation for high apical thrombus/stroke risk |
| CMR Parametric Mapping | Native T1 & Extracellular Volume (ECV) | Low Native T1 = Fabry Disease; Very High Native T1 & ECV >40% = ATTR/AL Amyloidosis; Elevated ECV = diffuse HCM fibrosis |
| 2D STE (Strain) | GLS & Mechanical Dispersion | Differentiates phenocopies (polar map); LVEF <50% (“End-Stage HCM”) = Class IIa ICD indication |
| Circulating Biomarkers | NT-proBNP & High-Sensitivity Troponin (hs-cTnI/T) | Reflects wall stress & microvascular injury; useful efficacy markers during Mavacamten therapy (safety monitoring relies on echocardiographic LVEF) |
IVADVANCES IN GENOMIC MEDICINE AND PHENOCOPY EXCLUSION
- Targeted Next-Generation Sequencing (NGS) Panels (Class I): Identifies pathogenic variants in the eight core sarcomeric genes (MYBPC3 [~40–45%, predominantly truncating/haploinsufficiency] and MYH7 [~30–35%, predominantly missense], plus TNNT2, TNNI3, TPM1, MYL2, MYL3, ACTC1) in 40 to 60 percent of familial cases, enabling cascade genetic screening of first-degree relatives.
- Crucial Exclusion of Actionable HCM Phenocopies (“Sarcomere-Negative LVH”): NGS panels simultaneously screen for non-sarcomeric metabolic and infiltrative mimics that have specific disease-modifying therapies: Anderson-Fabry Disease (GLA — treated with enzyme replacement [agalsidase] or chaperone therapy [migalastat]), Hereditary/Wild-Type ATTR Amyloidosis (TTR — treated with tafamidis, acoramidis, or vutrisiran), Danon Disease (LAMP2 — X-linked lysosomal glycogen storage with massive LVH [often >30–40 mm], WPW pre-excitation, and rapid progression to transplant in young males), PRKAG2 Cardiomyopathy (glycogen storage + WPW + early conduction block requiring pacemaker/ICD), Pompe Disease (GAA), Friedreich Ataxia (FXN — omaveloxolone), and Noonan/RASopathies (PTPN11, RAF1).
- Polygenic Modifiers in “Genotype-Negative” HCM: Genome-wide association studies (Harper et al., Tadros et al., Nature Genetics 2021) prove that the ~40 to 50 percent of HCM patients with negative sarcomere gene panels largely have polygenic HCM driven by a high Polygenic Risk Score (PRS) interacting with diastolic blood pressure and central obesity, which also explains why carriers of the same MYBPC3 variant within one family exhibit vastly different wall thicknesses.
VBIOMARKER PROFILING IN SURVEILLANCE AND MYOSIN INHIBITOR THERAPY
- High-Sensitivity Cardiac Troponin (hs-cTnT/I) and NT-proBNP: Elevated in 30 to 70 percent of stable HCM patients; hs-cTn reflects ongoing subendocardial microvascular ischemia and myocyte necrosis (correlating with LGE progression and exercise hypotension), while NT-proBNP reflects LVOT gradient, diastolic filling pressure, and wall stress.
- Pharmacodynamic Biomarkers for Cardiac Myosin Inhibitors: In the EXPLORER-HCM (Mavacamten) and SEQUOIA-HCM (Aficamten, NEJM 2024) trials, cardiac myosin inhibition produced a rapid 65 to 80 percent reduction in NT-proBNP and a 40 to 50 percent reduction in hs-cTnI paralleling relief of LVOT obstruction.
Key references
- Ommen SR, Ho CY, Asif IM, et al.: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy, Circulation / Journal of the American College of Cardiology, 2024.
- Arbelo E, Protonotarios A, Gimeno JR, et al.: 2023 ESC Guidelines for the management of cardiomyopathies, European Heart Journal, 2023.
- Ko WY, Siontis KC, Attia ZI, et al.: Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled Electrocardiogram, Journal of the American College of Cardiology, 2020.
- Maron MS, Masri A, Choudhury L, et al. (SEQUOIA-HCM Investigators): Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy, New England Journal of Medicine, 2024.
meritmedscript.comDr. Sidhartha Mullapudi
